Climb Bio Q2 cash $187.4M, R&D $6.6M; budoprutug trials underway; new CMO

Climb Bio, Inc.

2025-Q2 EPS reported -$0.44

Cash and marketable securities $187.4M as of June 30, 2025; cash runway expected through 2027.
R&D expenses $6.6M in Q2 2025 vs $1.0M in Q2 2024; no acquired IPR&D expense in 2025.
Budoprutug ITP and SLE trials dosing patients; pMN Phase 2 to initiate; SC formulation Phase 1 data expected H1 2026.
CLYM116 investor event September 2025 with preclinical data; IND/CTA for IgAN expected H2 2025.
Edgar D. Charles, M.D., MSc appointed CMO, joining from Bristol Myers Squibb in June 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.